The study serves to determine whether the treatment of patients with stable, symptomatic
Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is
efficient and safe. The efficacy and safety of the drug will be tested against a placebo
treatment.
The primary criterion to assess efficacy will be the difference between the serial lung
function measurements of patients who have been treated for 12 weeks with NVA237 versus those
that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1
testing) will be conducted and the "area under the curve" will be the measure for the ability
to breathe.